Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health 

                    Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice is hereby given of the following meeting.                          ( print page 2703)    

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for type 1 diabetes. The outcome of the evaluation will be a decision whether NIDDK should support the request and make available contract resources for development of the potential therapeutic to improve the treatment or prevent the development of type 1 diabetes and its complications. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         Type 1 Diabetes—Rapid Access to Intervention Development Special Emphasis Panel; National Institute of Diabetes and Digestive and Kidney Diseases.                    

*Date:*                         January 23, 2007.                    

*Time:*                         3 p.m. to 4 p.m.                     

*Agenda:*                         To evaluate requests for preclinical development resources for potential new therapeutics for type 1 diabetes and its complications.                    

*Place:*                         6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).                    

*Contact Person:*                         Dr. Myrlene Staten, Senior Advisor, Diabetes Transplation Research, Division of Diabetes, Endocrinology and Metabolic Diseases, NIDDK, NIH, 6707 Democracy Boulevard, Bethesda, MD 20892-5460, 301 402-7886.                     

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 98.849, Kidney Diseases, urology and Hematology Research, National Institutes of Health, HHS)

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Dated: January 11, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory Committee Policy. 

[FR Doc. 07-235 Filed 1-19-07; 8:45 am]

BILLING CODE 4140-01-M